Evolocumab to shrink plaque in early heart disease
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether evolocumab, a monthly injection, can shrink the fatty buildup (plaque) in your heart arteries. It is for people who have early signs of heart disease or diabetes but have not had a heart attack or stroke yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have signs of early heart disease (like a heart scan showing calcium or mild blockages) or have diabetes or peripheral artery disease.
- Your LDL ('bad') cholesterol must be at least 70 mg/dL.
- You need to be on a stable cholesterol medication (like a statin) for at least 6 weeks, with no planned changes.
- You must not have ever had a heart attack, stroke, or stent/bypass surgery.
- You must be able to have a CT scan of your heart (no kidney problems, no contrast allergy, and can hold your breath).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether starting evolocumab (a cholesterol-lowering injection) soon after a heart attack helps prevent future heart problems. You'll receive the study drug or placebo for 52 weeks while your heart is monitored with imaging scans.
This study tests whether a purified omega-3 fatty acid called icosapent ethyl can reduce inflammation and shrink high-risk plaques in your heart arteries. It uses a special PET/CT scan to see if the medicine helps stabilize these plaques over time.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study tests whether a cholesterol-lowering injection (alirocumab) helps people who are on regular dialysis. It aims to improve cholesterol control in a carefully selected group and tracks safety during treatment.
This trial tests whether adding a special scan to look at the fatty plaque in your arteries can help your doctor decide if you need stronger heart medication to prevent future heart attacks or strokes. If you have moderate blockages and signs of inflammation, you may be able to join.
This study tests whether a new injectable cholesterol-lowering drug (called a PCSK9 inhibitor) can help prevent further heart problems by making plaque in your arteries more stable and less likely to cause blocked vessels. It is for people who recently had a heart attack or unstable angina and already received a stent in the blocked artery.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.